Charles Koller

20.0k citations

239 papers · 15.1k indexed · 4 hit papers · h-index 65

Impact in

Genetics top 0.02%
- Chronic Lymphocytic Leukemia Research
Hematology top 0.05%
- Acute Myeloid Leukemia Research
- Chronic Myeloid Leukemia Treatments
- Hematopoietic Stem Cell Transplantation

Papers in

Genetics 144
- Chronic Lymphocytic Leukemia Research 121
- Myeloproliferative Neoplasms: Diagnosis and Treatment 16
Hematology 129
- Acute Myeloid Leukemia Research 72
- Chronic Myeloid Leukemia Treatments 62

Co-authors: Hagop M. Kantarjian Michael J. Keating Jörge E. Cortes Susan O’Brien Francis J. Giles Elihu H. Estey Deborah A. Thomas Miloslav Beran
Journals: Blood (103 papers)Cancer (28 papers)Journal of Clinical Oncology (24 papers)Leukemia (8 papers)Leukemia Research (5 papers)
Partner nations: United States Germany Belgium

In The Last Decade

Charles Koller

237 papers receiving 14.6k citations

Hit Papers

align trajectories log scale

Early Results of a Chemoimmunotherapy Regimen of Fludarabine, Cyclophosphamide, and Rituximab As Initial Therapy for Chronic Lymphocytic Leukemia 2005 · 704 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2005 Journal of Clinical Oncology
2000 Journal of Clinical Oncology
2000 Blood
1997 Blood

Peers

Countries citing papers authored by Charles Koller

Since Specialization

Citations

This map shows the geographic impact of Charles Koller's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Charles Koller with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Charles Koller more than expected).

Fields of papers citing papers by Charles Koller

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Charles Koller. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Charles Koller. The network helps show where Charles Koller may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Charles Koller, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Charles Koller Line = papers co-authored together Charles Koller links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Dasatinib Combined with Interferon-alfa Induces a Complete Cytogenetic Response and Major Molecular Response in a Patient with Chronic Myelogenous Leukemia Harboring the T315I BCR-ABL1 Mutation Clinical Lymphoma Myeloma & Leukemia ·A. Megan Cornelison, 汪韬 Wang Tao, Charles Koller, Elias Jabbour	2011	11
2	Survival outcomes for clonal evolution in chronic myeloid leukemia patients on second generation tyrosine kinase inhibitor therapy Cancer ·Dushyant Verma, Hagop M. Kantarjian, Jianqin Shan, Susan O’Brien, Zeev Estrov, Guillermo Garcia‐Manero, Charles Koller, Gautam Borthakur, Jörge E. Cortes	2010	39
3	The effect of interleukin 11 on thrombocytopenia associated with tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia Cancer ·Ahmed Aribi, Hagop M. Kantarjian, Charles Koller, Deborah A. Thomas, Stefan Faderl, Guillermo Garcia‐Manero, Jörge E. Cortes	2008	10
4	Multiple‐dose granulocyte‐macrophage–colony‐stimulating factor plus 23‐valent polysaccharide pneumococcal vaccine in patients with chronic lymphocytic leukemia Cancer ·Amar Safdar, Gilhen Rodriguez, Adriana M. Rueda, William G. Wierda, Alessandra Ferrajoli, Daniel M. Musher, Susan O’Brien, Charles Koller, Gerald P. Bodey, Michael J. Keating	2008	30
5	Phase 1 study of lonafarnib (SCH 66336) and imatinib mesylate in patients with chronic myeloid leukemia who have failed prior single‐agent therapy with imatinib Cancer ·Jörge E. Cortes, Elias Jabbour, George Q. Daley, Susan O’Brien, Srđan Verstovšek, Alessandra Ferrajoli, Charles Koller, Yali Zhu, Paul Statkevich, Hagop M. Kantarjian	2007	40
6	Combination therapy with arsenic trioxide, all‐trans retinoic acid, and gemtuzumab ozogamicin in recurrent acute promyelocytic leukemia Cancer ·Ahmed Aribi, Hagop M. Kantarjian, Elihu H. Estey, Charles Koller, Deborah A. Thomas, Steven M. Kornblau, Stefan Faderl, Rike Lamb, Guillermo Garcia‐Manero, Jörge E. Cortes	2007	69
7	The role of craniospinal irradiation in adults with a central nervous system recurrence of leukemia Cancer ·Kevin Sanders, Chul S. Ha, Jörge E. Cortes, Charles Koller, Hagop M. Kantarjian, James D. Cox	2004	29
8	Liposomal amphotericin B versus the combination of fluconazole and itraconazole as prophylaxis for invasive fungal infections during induction Cancer ·Gloria Mattiuzzi, Elihu H. Estey, Issam Raad, Francis J. Giles, Jörge E. Cortes, Yu Shen, Dimitrios P. Kontoyiannis, Charles Koller, Mark F. Munsell, Miloslav Beran, Hagop M. Kantarjian	2003	62
9	“T-Cell-Rich B-Cell Lymphoproliferative Disorder” of the Bone Marrow Leukemia & lymphoma ·Jesús Muñoz, Susan O’Brien, Emil J. Freireich, Silvia Liberatore, Hagop M. Kantarjian, Charles Koller, Michael J. Keating, Maher Albitar	2001	1
10	Primary refractory and relapsed adult acute lymphoblastic leukemia Cancer ·Deborah A. Thomas, Hagop M. Kantarjian, Terry L. Smith, Charles Koller, Jörge E. Cortes, Susan O’Brien, Francis J. Giles, James Gajewski, Sherry Pierce, Michael J. Keating	1999	144
11	Influenza Among Hospitalized Adults with Leukemia Clinical Infectious Diseases ·N. V. Korotkevych, Janet A. Englund, Robert B. Couch, Kenneth V. I. Rolston, Mario A. Luna, James Goodrich, Victor Lewis, Nadeem Q. Mirza, Michael Andreeff, Charles Koller, Linda S. Elting, Gerald P. Bodey, Estella Whimbey	1997	93
12	All-trans retinoic acid followed by chemotherapy for salvage of refractory or relapsed acute promyelocytic leukemia Cancer ·Jörge E. Cortes, Hagop M. Kantarjian, Susan O’Brien, L. E. Robertson, Charles Koller, S. Rou-Jui Hu, Sanford A. Stass, Michael J. Keating, Elihu H. Estey	1994	36
13	Lack of Effect of 2-Chlorodeoxyadenosine Therapy in Patients with Chronic Lymphocytic Leukemia Refractory to Fludarabine Therapy New England Journal of Medicine ·Susan O’Brien, Hagop M. Kantarjian, Elihu H. Estey, Charles Koller, Mi Ae Han, Miloslav Beran, Michael Andreeff, Sherry Pierce, Michael J. Keating	1994	73
14	An open trial of cefoperazone plus sulbactam for the treatment of fever in cancer patients Journal of Antimicrobial Chemotherapy ·Gerald P. Bodey, Linda S. Elting, 徐志得, Charles Koller, Susan O’Brien, Elihu H. Estey, Robert S. Benjamin	1993	20
15	Determination of Plicamycin in Plasma by Radioimmunoassay Therapeutic Drug Monitoring ·Kang Fang, Charles Koller, N Brown, Elemer Nagy, Reonardo Chariglione, Bertrand Leclair	1992	9
16	Differential dose‐related haematological effects of GM‐CSF in pancytopenia: evidence supporting the advantage of low‐ over high‐dose administration in selected patients British Journal of Haematology ·Razelle Kurzrock, Moshe Talpaz, Maitane Nieto-Retuerto, Elihu H. Estey, Susan O’Brien, Cheryl Hirsch‐Ginsberg, Charles Koller, Emil J. Freireich, Jordan U. Gutterman	1991	28
17	Mithramycin blocks protein binding and function of the SV40 early promoter. Journal of Clinical Investigation ·Ratna B. Ray, Richard C. Snyder, Shelia D. Thomas, Charles Koller, Donald M. Miller	1989	113
18	Relapse of adult acute myelogenous leukemia isolated in testicle. PubMed ·X.-L. Li, Charles Koller, K. B. McCredie	1989	2
19	Molecular analysis of chromosome 22 breakpoints in adult Philadelphia-positive acute lymphoblastic leukaemia British Journal of Haematology ·Razelle Kurzrock, Mordechai Shtalrid, J. U. Gutterman, Charles Koller, Ronald S. Walters, José M. Trujillo, Moshe Talpaz	1987	29
20	Treatment of acute lymphoblastic leukemia with 2'-deoxycoformycin: clinical and biochemical consequences of adenosine deaminase inhibition. Munich Personal RePEc Archive (Ludwig Maximilian University of Munich) ·Charles Koller, Barry Mitchell, Michael R. Grever, Edward Sallis, Louis Malspeis, Earl N. Metz	1979	45

About Charles Koller

Charles Koller is a scholar working on Genetics, Hematology, Pathology and Forensic Medicine, Public Health, Environmental and Occupational Health and Immunology, having authored 239 papers that have together received 15.1k indexed citations. Recurring topics across this work include Chronic Lymphocytic Leukemia Research (121 papers), Acute Myeloid Leukemia Research (72 papers), Chronic Myeloid Leukemia Treatments (62 papers), Lymphoma Diagnosis and Treatment (57 papers), Acute Lymphoblastic Leukemia research (55 papers), Immunodeficiency and Autoimmune Disorders (29 papers), Eosinophilic Disorders and Syndromes (23 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (16 papers). The work is most often cited by research in Genetics (7.5k citations), Hematology (6.8k citations), Pathology and Forensic Medicine (4.7k citations), Immunology (3.3k citations) and Oncology (3.0k citations). Charles Koller has collaborated with scholars based in United States, Germany and Belgium. Frequent co-authors include Hagop M. Kantarjian, Michael J. Keating, Jörge E. Cortes, Susan O’Brien, Francis J. Giles, Elihu H. Estey, Deborah A. Thomas, Miloslav Beran, Susan Lerner and Stefan Faderl. Their work appears in journals such as Blood, Cancer, Journal of Clinical Oncology, Leukemia and Leukemia Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact